Market Place
Sourcing Support
Nuvation Bio Completes Acquisition of AnHeart Therapeutics
10 Apr 2024 //
BUSINESSWIRE
Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction
25 Mar 2024 //
BUSINESSWIRE
Innovent and AnHeart Announce the NMPA Has Accepted NDA for Taletrectinib
05 Mar 2024 //
PR NEWSWIRE
AnHeart and Innovent Announce NMPA has Accepted Second NDA for Taletrectinib
04 Mar 2024 //
BUSINESSWIRE
AnHeart and Innovent Announce NMPA Has Granted Taletrectinib Priority Review
18 Dec 2023 //
BUSINESSWIRE
AnHeart Therapeutics and Foundation Medicine Announce Collaboration
14 Dec 2023 //
BUSINESSWIRE
AnHeart Therapeutics Expands Leadership With Development and Commercial Leads
09 Nov 2023 //
BUSINESSWIRE
AnHeart Announces Agreement With Nippon Kayaku for Taletrectinib in Japan
30 Oct 2023 //
BUSINESSWIRE
AnHeart Therapeutics’ Taletrectinib Shrank Tumors in More Than 90% of People
21 Oct 2023 //
BUSINESSWIRE
AnHeart Appoints Charlotte Arnold as Chief Corporate Affairs Officer
28 Sep 2023 //
BUSINESSWIRE
AnHeart Announces Initiation of Global Phase 2 Trial Evaluating Safusidenib
07 Sep 2023 //
BUSINESSWIRE
AnHeart Therapeutics Appoints Edward Lang Jr. as Chief Business Officer
03 Apr 2023 //
BUSINESSWIRE
AnHeart Therapeutics Presents Updated Efficacy and Safety of Taletrectinib
31 Mar 2023 //
BUSINESSWIRE
AnHeart Announces Presentation at the European Lung Cancer Congress (ELCC) 2023
13 Mar 2023 //
BUSINESSWIRE
AnHeart Therapeutics Announces Publication of Taletrectinib Global Phase 2 Trial
09 Mar 2023 //
BUSINESSWIRE
Guardant and AnHeart Announce Collaboration to Develop Guardant360 CDx
02 Feb 2023 //
BUSINESSWIRE
AnHeart Receives FDA Clearance of IND to Initiate PII Study of Safusidenib
15 Dec 2022 //
BUSINESSWIRE
AnHeart Expands US Team with Appointments in Research and Medical Affairs
19 Oct 2022 //
BUSINESSWIRE
AnHeart & NewG Lab Receive Orphan Drug Designation for Taletrectinib
12 Sep 2022 //
BUSINESSWIRE
AnHeart Tx to Present Poster and Host Investigator Meeting at WCLC 2022
04 Aug 2022 //
BUSINESSWIRE
AnHeart Receives FDA Breakthrough Therapy Designation
03 Aug 2022 //
BUSINESSWIRE
AnHeart Therapeutics Appoints Dr. Shuanglian Li as Chief Medical Officer (US)
01 Aug 2022 //
BUSINESSWIRE
AnHeart & Innovent Present Updated PII Efficacy and Safety Data of Taletrectinib
06 Jun 2022 //
BUSINESSWIRE
AnHeart Therapeutics Announces Presentation at ELCC 2022
21 Mar 2022 //
BUSINESSWIRE
AnHeart Therapeutics Announces First Patient Dosed in Global Phase 2 TRUST-II
25 Oct 2021 //
BUSINESSWIRE
AnHeart Therapeutics Launches Study to Evaluate AXL inhibitor AB-329
18 Oct 2021 //
BUSINESSWIRE
Evelo touts PhII win; Innovent, AnHeart claim interim PhII success
27 Sep 2021 //
ENDPTS
Innovent and AnHeart Announce Interim Data from Phase 2 Trial of Taletrectinib
25 Sep 2021 //
ASIAONE
First Patient Dosed in Phase II Basket Trial of Taletrectinib
17 Jun 2021 //
GLOBENEWSWIRE
Innovent & AnHeart Release Preliminary Results from PhII Trial of Taletrectinib
07 Jun 2021 //
GLOBENEWSWIRE
AnHeart Announces Publication of Pooled Analysis of two Phase 1 Studies
29 Oct 2020 //
BIOSPACE
AnHeart to acquire rights to two clinical stage oncology candidates from Daiichi
08 Sep 2020 //
PHARMABIZ
